Empirical therapy advisor

Before culture results are back: how likely is each antibiotic to cover the pathogen of a patient like this one, in this ward, given the last 12 months of results and today's alerts.

Patient

Based on 1246 first isolates · PHC-N · Cystitis (lower UTI) · 2025-09-28 → 2026-09-27
Health centre North
Per-organism detail: PHC-N urine resistance view →
Narrowest option reaching 80 % coverage, no active warning
nitrofurantoin 83 % (80 %–85 %)
No tissue or blood levels: cystitis only.
Not covered: Proteus mirabilis (7 %), Pseudomonas aeruginosa (5 %), Klebsiella pneumoniae (4 %)
AntibioticCoverage, 12 months (95 % CI)12 mo4 wk
nitrofurantoin NIT
trend · Escherichia coli lower UTI only
83 %
84 %
n = 124
meropenem MEM
trend · Escherichia coli reserve
82 %
84 %
n = 124
piperacillin-tazobactam TZP
trend · Escherichia coli broad spectrum
79 %
78 %
n = 124
mecillinam MEC
trend · Escherichia coli lower UTI only
75 %
75 %
n = 124
ciprofloxacin CIP
trend · Escherichia coli
75 %
75 %
n = 124
ceftriaxone CRO
trend · Escherichia coli
74 %
73 %
n = 124
trimethoprim TMP
trend · Escherichia coli lower UTI only
71 %
73 %
n = 124
70 %
69 %
n = 124
51 %
59 %
n = 124
vancomycin VAN
trend · Enterococcus faecalis Gram-positive only
15 %
15 %
n = 124
5 %
6 %
n = 124
clindamycin CLI
trend · Staphylococcus aureus Gram-positive only
4 %
4 %
n = 124

Most likely organisms for this profile

Escherichia coli
50 %
Klebsiella pneumoniae
13 %
Enterococcus faecalis
11 %
Proteus mirabilis
7 %
Pseudomonas aeruginosa
5 %
Citrobacter freundii
4 %

Decision support only: coverage is the share of first isolates from similar patients that were susceptible (an organism not tested for a drug counts as not covered). It does not replace local treatment guidelines, allergy and severity assessment, or clinical judgement. The black tick on each bar is the coverage target; the bracket is the 95 % confidence interval.

AEI · Tyks Laboratoriot × Mylab · JunctionX Turku. Synteettinen aineisto; EARS-Net-luvut: ECDC.